August 3, 2023 – HemoSonics®, a medical device technology company focused on acute bleeding management, announced its Quantra® Hemostasis System has received an Innovative Technology contract award from Vizient. Vizient members include more than half of all acute care hospitals in the United States, including 97% of U.S. academic medical centers.
The Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer with QPlus® and QStat® Cartridges. The system provides a comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes. Doctors don’t need to wait on test results during critical, complex surgeries, and patients receive optimized intervention as quickly as possible. Quantra is FDA-cleared for use in point-of-care settings like operating rooms and intensive care units, as well as hospital laboratories and requires minimal resources to maintain, operate, and interpret. HemoSonics’ medical device technology can help patients and hospitals: a 2023 Journal of Cardiothoracic Surgery study showed Quantra reduced blood component use between 10% and >90%. In addition, the cost of blood products decreased by 41%.
Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program. Vizient member-led councils identify technologies that have the potential to enhance clinical care, patient safety, and healthcare worker safety or improve the business operations of healthcare organizations. The contract sets terms for hospitals to evaluate and purchase the Quantra Hemostasis System, an innovative in vitro diagnostic platform that characterizes the coagulation properties of whole blood.